Skip to main content
NewslettersWatchlist

Hamilton Thorne Ltd(HTL-T)
TSX

Today's Change
Real-Time Last Update
Day Low2.23
Day High2.23
Open:2.23
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newsfile
Hamilton Thorne Provides Update on Going Private Transaction
GlobeNewswire
Hamilton Thorne Announces Shareholder Approval of Going Private Transaction
GlobeNewswire
Hamilton Thorne Announces Mailing of Meeting Materials and Receipt of Interim Order in Respect of Going Private Transaction
GlobeNewswire
Hamilton Thorne Reports Revenue for the Quarter and Six Months Ended June 30, 2024, and Confirms Annual Guidance
GlobeNewswire
Hamilton Thorne to Release Q2 2024 Financial Results on August 14, 2024
GlobeNewswire
Hamilton Thorne Announces Agreement to be Acquired by Astorg for CAD$2.25 Per Share in Cash
GlobeNewswire
Hamilton Thorne Reports Record Revenue and EBITDA for the Quarter Ended March 31, 2024, and Confirms Annual Guidance
AI-generated - The Globe and Mail
Hamilton Thorne: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (HTL)
GlobeNewswire
Hamilton Thorne to Announce Q1 2024 Financial Results and Hold Conference Call on May 14, 2024
AI-generated - The Globe and Mail
Hamilton Thorne: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (HTL)
Newsfile
Hamilton Thorne Ltd. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire
Hamilton Thorne Reports Record Revenue and EBITDA for the Quarter and Year Ended December 31, 2023
GlobeNewswire
Hamilton Thorne to Announce Q4 and Full Year 2023 Financial Results and Hold Conference Call on March 27, 2024
AI-generated - The Globe and Mail
Hamilton Thorne: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (HTL)
GlobeNewswire
Hamilton Thorne Appoints Dr. Ekaterina (Kate) Torchilin as President and CEO
AI-generated - The Globe and Mail
Hamilton Thorne: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (HTL)
GlobeNewswire
Hamilton Thorne Reports Revenue for the Quarter and Nine Months Ended September 30, 2023
GlobeNewswire
Hamilton Thorne to Announce Q3 2023 Financial Results and Hold Conference Call on November 13, 2023
AI-generated - The Globe and Mail
Hamilton Thorne: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (HTL)
Newsfile
Hamilton Thorne Announces the Acquisition of Gynetics Medical Products N.V.
AI-generated - The Globe and Mail
Hamilton Thorne: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (HTL)
PR Newswire
Hamilton Thorne Ltd. Opens the Market

Profile

Hamilton Thorne Ltd is engaged in providing precision instruments, consumables, software, and services that reduce cost, increase productivity, improve results, and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. The company markets its products and services under the Hamilton Thorne, Gynemed, and Embryotech Laboratories brands, through its growing sales force and distributors. The company's customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments. It has a single reporting segment being Engaged in Sales to the ART, Research, and Cell Biology Markets.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.